March 25, 2019 —BOSTON, MA. and STOCKHOLM, SWEDEN, March 25, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the appointment of Dr. Eyal C.

February 27, 2019 —Janus Henderson Investors joins Investor Group   BOSTON, MA. and STOCKHOLM, SWEDEN, February 27, 2019 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced that funds managed

January 7, 2019 —BOSTON, MA., and STOCKHOLM, SWEDEN, January 7, 2019 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.

December 2, 2018 —BOSTON, MA. and STOCKHOLM, SWEDEN, November 30, 2018 – Aprea Therapeutics, a clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, today announced the closing of a EUR 50 million Series C financing round led by the

December 2, 2018 — 95% ORR (by IWG) in 20 evaluable patients 70% complete remission (CR) rate in 20 evaluable patients No dose-limiting toxicities to date       BOSTON, MA. and STOCKHOLM, SWEDEN, December 2, 2018 – Aprea Therapeutics presented results at the 2018 ASH Annual Meeting from its Phase

June 17, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 European Hematology Association (EHA) Annual Meeting in Stockholm ORR (by IWG) of 100% in all evaluable

April 16, 2018 — Aprea Therapeutics Presents Results From Phase Ib/II Clinical Study of APR-246 and Azacitidine (AZA) in Patients with  TP53  Mutant Myelodysplastic Syndromes (MDS) at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago   ORR (by IWG) of 100% in all

January 4, 2018 —BOSTON, MA., and STOCKHOLM, SWEDEN, January 4, 2018 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced that Christian S.

October 16, 2017 —BOSTON, MA. and STOCKHOLM, SWEDEN, October 16, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patients were enrolled in a Phase

August 2, 2017 —BOSTON, MA. and STOCKHOLM, SWEDEN, August 2, 2017 – Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, announced today that the first patient was enrolled in a Phase Ib/II